We are comparing a new direct oral anticoagulant with a standard vitamin K antagonist in patients with intra-cardiac thrombus. The goal is to see which treatment better reduces complications and promotes thrombus regression.
We are studying Asciminib, alone or with Nilotinib, for adults with BCR-ABL1+ Chronic Myeloid Leukemia. The goal is to see if this treatment helps achieve better disease control and improves quality of life.
We are testing the medication sarilumab in children and adolescents with systemic juvenile idiopathic arthritis to find the best dose and understand its effects and safety.
We are testing a new treatment called YTB323 for people with Relapsing Multiple Sclerosis who have had ongoing disease activity despite previous therapies. The study aims to assess its safety and effects on disease progression.
We are studying the long-term safety of INZ-701 in patients with ENPP1 and ABCC6 deficiencies. This trial will help us understand how the drug works over time and its effects on certain blood markers.
We are investigating whether adding a special chemotherapy during surgery helps prevent cancer recurrence in patients with colon cancer that has spread to the abdomen. This study compares outcomes for those receiving this treatment versus standard care.
We are comparing a topical cream to an injection for pain relief in women with first-degree perineal tears after childbirth. The goal is to see which method provides better comfort during and after the repair.
We are studying whether pemigatinib can help patients with recurrent or metastatic solid tumors that have a specific gene change. The trial aims to assess its effects on tumor growth and overall patient health.
We are exploring a new treatment called CEB-01 for people with pancreatic cancer to see how safe it is and if it may help improve their condition.
We are studying the safety of rimegepant for treating migraines in children and adolescents aged 6 to under 18. This trial will help us understand how well the medication works and if there are any side effects.
We are investigating whether Landiolol can improve blood flow and heart function in patients with septic shock. This study compares its effects to standard treatments for managing rapid heart rates.
We are studying how well tedizolid works compared to linezolide in reducing tuberculosis bacteria in patients. This trial aims to find out which treatment may be more effective in the first days of therapy.
We are studying a new anticancer drug, VERT-002, for patients with advanced solid tumors, including lung cancer with MET alterations. The trial aims to assess its safety and how well it may work.
We are studying how well Creon® helps patients with pancreatic exocrine insufficiency after surgery. The goal is to see if it improves symptoms and nutritional health.
We are studying a treatment combining surgery and chemotherapy for patients with inguinal lymph node metastases. The goal is to see if this approach improves survival and reduces the chance of cancer returning.
We are studying a new combination of medications for patients with heart attacks in critical condition. The goal is to see if this treatment can prevent blood clots while keeping bleeding risks low.
We are studying a new targeted therapy for children with somatostatin receptor-positive tumors to find the right dose and evaluate its safety. This trial will also look at how well the treatment works compared to standard care.
We are studying a new treatment for patients with late relapse of diffuse large B-cell lymphoma to see if it improves their condition and quality of life. The trial also looks at the safety of this treatment.
We are studying whether vaginal progesterone helps women achieve live births after frozen embryo transfer. The trial compares outcomes between those receiving progesterone and those who do not.
We are testing a new imaging method to see how well it identifies clinically significant prostate cancer. This may help improve diagnosis accuracy for patients.